NCT01756950View on ClinicalTrials.gov

Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

2 mg/kg CR8020

administered as a single 2-hour intravenous infusion

BIOLOGICAL

5 mg/kg CR8020

administered as a single 2-hour intravenous infusion

BIOLOGICAL

15 mg/kg CR8020

administered as a single 2-hour intravenous infusion

BIOLOGICAL

30 mg/kg CR8020

administered as a single 2-hour intravenous infusion

BIOLOGICAL

50 mg/kg CR8020

administered as a single 2-hour intravenous infusion

BIOLOGICAL

Placebo

administered as a single 2-hour intravenous infusion

Trial Locations (1)

66211

Quintiles Early Clinical Development, Overland Park

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Crucell Holland BV

INDUSTRY

NCT01756950 - Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses | Biotech Hunter | Biotech Hunter